MARLBOROUGH, Mass., July 21, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that it will present a poster at the 2016 Summer Meeting of the American Academy of Dermatology (AAD). This meeting will bring together the best minds in dermatology to be immersed in an innovative program that includes presentations by renowned experts on topics that impact dermatologists today. The Summer AAD meeting will be held July 28-31, 2016 at the Hynes Convention Center in Boston, MA.
On Friday, July 29, 2016, at 2:40 p.m. EDT, during the Infection-Viral Poster Session, Dr. Karen Bulock, RXi's Vice President of Research will give an oral presentation entitled, "Diphenylcyclopropenone Ointment for the Treatment of Common Warts". Diphenylcyclopropenone (DPCP) is a potent topical immunotherapy agent that has been used since the late 1970's by physicians for the treatment of common warts, alopecia areata, and cutaneous metastases of melanoma. As DPCP has not yet been evaluated and approved by a regulatory agency, RXi Pharmaceuticals has developed Samcyprone™, a therapeutic consisting of a proprietary ointment formulation of DPCP based on technology that was licensed from Hapten Pharmaceuticals. A summary of the proof of concept study and an update on the status of the Company's ongoing Phase 2 study for cutaneous warts, RXI-SCP-1502, will be provided.
The poster will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation.
About the American Academy of Dermatology
The American Academy of Dermatology was founded in 1938. It is the largest, most influential and most representative dermatology group in the United States. With a membership of more than 17,000, it represents virtually all practicing dermatologists in the United States, as well as a growing number of international dermatologists. The Academy is committed to advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.